TrovaGene Inc Share Price Nasdaq
Equities
US8972383090
Biotechnology & Medical Research
Sales 2024 * | 242K 20.24M | Sales 2025 * | 66.67K 5.56M | Capitalization | 195M 16.27B |
---|---|---|---|---|---|
Net income 2024 * | -46M -3.84B | Net income 2025 * | -57M -4.76B | EV / Sales 2024 * | 804 x |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 2,924 x |
P/E ratio 2024 * |
-4.47
x | P/E ratio 2025 * |
-4.14
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 92.32% |
Latest transcript on TrovaGene Inc
Managers | Title | Age | Since |
---|---|---|---|
Mark Erlander
CEO | Chief Executive Officer | 64 | 04/13/04 |
James Levine
DFI | Director of Finance/CFO | 53 | 12/21/12 |
Tod Smeal
CTO | Chief Tech/Sci/R&D Officer | 59 | 11/22/11 |
Members of the board | Title | Age | Since |
---|---|---|---|
James Armitage
BRD | Director/Board Member | 77 | 22/20/22 |
Gary Pace
BRD | Director/Board Member | 76 | 22/20/22 |
Mark Erlander
CEO | Chief Executive Officer | 64 | 04/13/04 |
1st Jan change | Capi. | |
---|---|---|
+0.17% | 42.19B | |
+10.92% | 42.24B | |
+44.30% | 40.15B | |
-6.20% | 28.31B | |
+5.23% | 24.63B | |
-24.79% | 18.2B | |
+26.69% | 12.01B | |
-3.13% | 11.76B | |
+6.57% | 10.4B |